Incidence of esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib in healthy volunteers: a prospective randomized comparative trial - Clinical trial for the incidence of gastrointestinal lesions by selective COX-2 inhibitor

Second Department of Internal Medicine, Osaka Medical College0 个研究点目标入组 33 人开始时间: 2012年12月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Subjects who have active peptic ulcer or gastrointestinal bleeding and need endoscopic treatment immediately 2) Subjects with significant hepatic disease, renal disease, heart disease or respiratory disease 3) Subjects with a history of gastrointestinal surgery other than appendectomy 4) Subjects orally taking or planning to orally take drug other than loxoprofen, etodolac, celecoxib or famotidine 5) Subjects with alcohol or chemical dependencies 6) Subjects with a history of intestinal obstruction, or person with suspected gastrointestinal obstruction on other tests 7)Subjects who cannot agree that surgery may be required if capsule endoscope retained in the body 8) Subjects whom otherwise the investigator determined ineligible as the subject

发起方

Second Department of Internal Medicine, Osaka Medical College